Invion logo

Invion(ASX) IVX

Market CapA$4.37MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2010)-100%
5 YearN/A
1 Year-62%
1 Month-12%
A$0.04
-5.00%
-0.00Today
Invion last closing stock price
MetricPriceDate
Last closeAUD 0.042026-10-09
Invion stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%AUD 0.042026-10-02
1 month-11.63%AUD 0.042026-09-09
3 month+2.7%AUD 0.042026-07-10
Year to date-59.14%AUD 0.092025-12-30
1 year-62%AUD 0.102025-10-07
Since inception-99.85%AUD 26.612010-02-15

Invion Financials at a Glance

Market Cap

A$4.37MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$384.71K

Net Income (TTM)

-A$14.44M

EPS (TTM)

-A$0.06

P/E Ratio

-0.64

Dividend

A$0.00

Beta (Volatility)

0.00 (Low)

Price

A$0.04

Volume

2,877

Open

A$0.04

Previous Close

A$0.04

Daily Range

A$0.04 - A$0.04

52-Week Range

A$0.03 - A$0.11

Estimated Earnings Date

Feb 26, 2026

IVX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Invion

Invion Limited is an Australian clinical-stage life sciences company focused on developing innovative photodynamic therapy (PDT) solutions for various cancer types. The company's flagship product, IVX-PDT, aims to treat skin cancers and solid tumors, supported by strategic partnerships with leading research institutions.

Products and Services
  • IVX-PDT: A photosensitizer agent targeting skin and solid tumors
  • Research collaborations with Hudson Institute and Peter MacCallum Cancer Centre
  • Focus on pre-clinical and in-vitro studies for ano-genital cancers
Growth Outlook
  • Partnerships with renowned research institutions enhance R&D capabilities
  • Potential market expansion as PDT gains recognition in oncology
  • Ongoing clinical trials may lead to significant product advancements
Financial Highlights
  • Recent quarterly revenue of AUD 384,707, showing initial market traction
  • Cash and cash equivalents increased to AUD 592,311, indicating liquidity
  • Operating expenses reflect ongoing investment in R&D for future growth
Invion Limited operates in the healthcare sector, specifically within drug manufacturing for specialty and generic applications. The company is headquartered in Melbourne and has been active since 2000. With a market capitalization of approximately AUD 4.26 million, Invion is positioned to leverage its innovative therapies in a growing market. The strategic alliances with prominent research institutions not only bolster its research capabilities but also enhance its credibility in the competitive landscape of cancer treatment. The recent financial data indicates a commitment to R&D, which is crucial for long-term growth and potential profitability. As the company continues to advance its clinical programs, it may attract further interest from investors looking for opportunities in the life sciences sector.
AI Generated • Sep 23, 2026

Industry

Pharmaceuticals

Sector

Health Care

CEO

Thian Chew, MBA

Website

www.inviongroup.com

Headquarters

Melbourne, VIC 3000, AU

IVX Financials

Key Financial Metrics (TTM)

Gross Margin

-347.68%

Operating Margin

-1472.22%

Net Income Margin

-1464.23%

Return on Equity

-102.18%

Return on Capital

-57.38%

Return on Assets

-68.97%

Earnings Yield

-1.56%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$4.37MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

109.20M

Volume

2.88K

Avg. Volume

65.29K

Financials (TTM)

Gross Profit

-A$2.63M

Operating Income

-A$10.95M

EBITDA

-A$7.94M

Operating Cash Flow

-A$5.34M

Capital Expenditure

-A$4.11K

Free Cash Flow

-A$5.35M

Cash & ST Invst.

A$592.31K

Total Debt

A$1.55M

Invion Performance Analysis

Invion annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-06-30AUD 4,104,71124.7%
20242024-06-30AUD 3,694,256-10.0%
20252025-06-30AUD 0N/A
20262026-06-30AUD 384,707N/A
Invion sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-31-100.0%
Q42025-06-30N/A
Q22025-12-31N/A
Q42026-06-30N/A
Invion annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-06-30AUD -0.03-32.4%
20242024-06-30AUD -0.09252.0%
20252025-06-30AUD -0.1238.9%
20262026-06-30AUD -0.06-48.8%
Invion sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-3163.7%
Q42025-06-30-225.5%
Q22025-12-3153.9%
Q42026-06-3049.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

A$384.71K

-73.8%

Gross Profit

-A$477.99K

-234.3%

Gross Margin

-1.24%

N/A

Market Cap

A$4.37MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$546.00K

N/A

Employees

8

N/A

Net Income

-A$2.07M

+57.9%

EBITDA

-A$1.32M

+70.8%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

A$592.31K

-24.4%

Total Debt

A$1.55M

N/A

Accounts Receivable

A$0.00

-100.0%

Inventory

A$0.00

N/A

Long Term Debt

A$0.00

N/A

Short Term Debt

A$1.55M

N/A

Return on Assets

-68.97%

N/A

Return on Invested Capital

-1.06%

N/A

Free Cash Flow

-A$1.11M

+4.3%

Operating Cash Flow

-A$1.10M

+4.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
PER.AXPercheron Therapeutics Limited
A$0.00+0.00%
CAN.AXCann Group Limited
A$0.01+0.00%
HIQ.AXHITIQ Limited
A$0.01+0.00%
BGT.AXBio-Gene Technology Limited
A$0.01+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TAT&T
$22.19-9.79%
WFFWf
$7.31+256.54%
VEEAVeea
$5.72+47.80%
SPCXSpace Exploration Technologies
$161.67+0.68%

Questions About IVX

What is the current price of Invion?

Invion is trading at A$0.04 per share.

What is the 52-week range for Invion?

Over the past 52 weeks, Invion has traded between A$0.03 and A$0.11.

How much debt does Invion have?

As of the most recent reporting period, Invion reported total debt of A$1.55M.

How much cash does Invion have on hand?

Invion reported A$592.31K in cash and cash equivalents in its most recent financial results.

What is Invion’s dividend yield?

Invion does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services